Marriage Of Kite’s CAR-T Platform To Amgen Targets Will Expand Pipeline For Both
This article was originally published in The Pink Sheet Daily
Executive Summary
Kite’s initial partnership with another biopharma sees it bringing its CAR-T platform technology to bear on Amgen’s oncology targets. Each company could develop new cancer immunotherapy products out of the collaboration, with earn-outs for the other.
You may also be interested in...
R&D Briefs: Alprolix Approval Bodes Well, T-VEC Stumbles, Curis Back On Track
FDA approves Biogen’s long-acting hemophilia drug Alprolix and lifts clinical hold on Curis’ cancer drug CUDC-427, but Amgen’s announcement that its melanoma vaccine T-VEC failed to improve survival clouds its chances with the agency.
PCPC Exploring Solutions With Chinese Authorities To Facilitate Cruelty-Free Cosmetic Imports
France plans to begin issuing manufacturing quality certificates so firms can import ordinary cosmetics into China without animal testing under a 2020 draft regulation. The Personal Care Products Council is working to find a comparable solution for US manufacturers.
Aurinia Launches Its First Drug With Lupkynis Approval For Lupus Nephritis
The calcineurin inhibitor, only the second drug to be approved by the US FDA for lupus nephritis, will be competing against GlaxoSmithKline’s Benlysta.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: